New treatment schemes for yaws: The path toward eradication

Clinical Infectious Diseases

Volumn 55, Issue 3, 2012, Pages 406-412

  Mitjà, Oriol ^a,b   Hays, Russell ^a   Rinaldi, Andrea C ^c   McDermot, Robyn ^d   Bassat, Quique ^b  

^a Lihir Medical Centre International SOS   (Papua New Guinea)

^b CENTRE FOR RESEARCH IN ENVIRONMENTAL EPIDEMIOLOGY CREAL   (Spain)

^c UNIVERSITY OF CAGLIARI   (Italy)

^d UNIVERSITY OF SOUTH AUSTRALIA   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ALBENDAZOLE; AZITHROMYCIN; BENZATHINE PENICILLIN; DOXYCYCLINE; ERYTHROMYCIN; IVERMECTIN; PENICILLIN G; PENICILLIN V; TETRACYCLINE;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; BLOODBORNE BACTERIUM; DISEASE CONTROL; DRUG BLOOD LEVEL; DRUG TISSUE LEVEL; HUMAN; PREVALENCE; PRIORITY JOURNAL; PUBLIC HEALTH PROBLEM; REVIEW; SINGLE DRUG DOSE; STANDARD; STREPTOCOCCUS PNEUMONIAE; TREATMENT FAILURE; WORLD HEALTH ORGANIZATION; YAWS;

ADMINISTRATION, ORAL; ANTI-BACTERIAL AGENTS; DISEASE ERADICATION; HUMANS; YAWS;

EID: 84863972955     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/cis444     Document Type: Review

References (45)

1. Mitjà O, Hays R, Ipai A, et al. Single-dose azithromycin versus benzathine benzylpenicillin for treatment of yaws in children in Papua New Guinea: an open-label, non-inferiority, randomised trial. Lancet 2012; 379:342-7.
2. World Health Organization. Accelerating work to overcome the global impact of neglected tropical diseases: a roadmap for implementation. Geneva, Switzerland: World Health Organization, 2012. Available at: http://whqlibdoc. who.int/hq/2012/WHO-HTM-NTD-2012.1-eng.pdf. Accessed 30 March 2012.
3. Perine PL, Hopkins DR, Niemel PLA, Feeley JC. Handbook of endemic treponematoses. Geneva, Switzerland: World Health Organization, 1984.
4. World Health Organization. Informal consultation on endemic treponematoses, 6-7 July 1995. (WHO/EMC/95.3). Geneva: World Health Organization, 1995.
5. Wirski WR. Surveillance and control of resurgent yaws in the African region. Rev Infect Dis 1985; 7:227-32.
6. Zahra A. Yaws in Southeast Asia: an overview. Rev Infect Dis 1985; 7:245-50.
7. World Health Organization. Yaws: a forgotten disease. WHO fact sheet no 316. Geneva, Switzerland: World Health Organization, 2012. Available at: http://www.who.int/neglected-diseases/diseases/yaws/en/index.html. Accessed 30 March 2012.
8. Eagle H, Fleishman R. The relative antisyphilitic activity of penicillins F, G, K, and X and of bacitracin, based on the amounts required to abort early syphilitic infections in rabbits. J Bacteriol 1948; 55:341-6.
9. World Health Organization Scientific Group. Treponemal infections. Technical report series no. 674. Geneva, Switzerland: World Health Organization, 1982.
10. Backhouse JL, Hudson BJ, Hamilton PA, Nesteroff SI. Failure of penicillin treatment of yaws on Karkar Island, Papua New Guinea. Am J Trop Med Hyg 1998; 59:388-92.
11. Anselmi M, Moreire JM, Caicedo C, Guderian R, Tognoni G. Community participation eliminates yaws in Ecuador. Trop Med Int Health 2003; 8:634-8.
12. Stamm L. Global challenge of antibiotic-resistant Treponema pallidum. Antimicrob Agents Chemother 2010; 54:583-9.
13. Manufacturer's recommendations: Bicillin L-A (Wyeth-Ayerst). In: Physicians' desk reference. 56th ed. Montvale, NJ: Medical Economics, 2002:2242-3.
14. Ballereau F, Prazuck T, Schrive I, et al. Stability of essential drugs in the field: results of a study conducted over a two-year period in Burkina Faso. Am J Trop Med Hyg 1997; 57:31-6.
15. Centers for Disease Control and Prevention. Recommendations of the International Task Force for Disease Eradication. MMWR 1993; 42:15.
16. Scolnik D, Aronson L, Lovinsky R, et al. Efficacy of a targeted, oral penicillin-based yaws control program among children living in rural South America. Clin Infect Dis 2003; 36:1232-8.
17. Ampofo O, Findlay GM. Aureomycin in the treatment of yaws and tropical ulcer in Africa. Nature 1950; 165:398-9.
18. Loughlin EH, Joseph A, Schaeffer K. Aureomycin in the treatment of yaws. Am J Trop Med Hyg 1951; 31:20-3.
19. Hill KR. The modern treatment of frambesia (yaws). West Indian Med J 1951; 1:81-92.
20. Brown WJ, Simpson WG, Moore MB, Price EV, Weinstein S. Oral propionyl erythromycin in treating early syphilis. Public Health Rep 1963; 78:911-7.
21. Gulati RK. Doxycycline in children?-the unanswered question. Pediatr Dermatol 2010; 27:419.
22. U.S. Food and Drug Administration, Division of Anti-Infectives Drug Products Advisory Committee. Briefing document for zithromax accelerated dosing; treatment of acute otitis media. November 7, 2001. Available at: http://www.fda.gov/downloads/advisorycommittees/committeesmeet. Accessed 15 May 2012.
23. Meheus AZ, Narain JP, Asiedu KB. Endemic treponematoses. In: Cohen J, Powderly SM, Opal WG, eds. Infectious diseases. 3rd ed. London: Elsevier, 2010; 104:1106-9.
24. Hinman AR, Hopkins DR. Lessons from previous eradication programs. In: Dowdle WR, Hopkins DR, eds. The eradication of infectious diseases: report of the Dahlen Workshop on the Eradication of Infectious Diseases. Clichester, UK: John Wiley & Sons, 1988: 19-32.
25. Hackett CJ, Guthe T. Some important aspects of yaws eradication. Bull World Health Organ 1956; 15:869-96.
26. Zahra A. Yaws eradication campaign in Nsukka Division, Eastern Nigeria. Bull World Health Organ 1956; 15:911-35.
27. Solomon AW, Holland MJ, Alexander NDE, et al. Mass treatment with single-dose azithromycin for trachoma. N Engl J Med 2004; 351:1962-71.
28. Bowden FG. Donovanosis in Australia: going, going . Sex Transm Infect 2005; 81:365-66.
29. Rekart M, Patrick D, Chakraborty B, et al. Targeted mass treatment for syphilis with oral azithromycin. Lancet 2003; 361:313-4.
30. Porco TC, Gebre T, Ayele B, et al. Effect of mass distribution of azithromycin for trachoma control on overall mortality in Ethiopian children: a randomized trial. JAMA 2009; 302:962-8.
31. Fry AM, Jha HC, Lietman M, et al. Adverse and beneficial secondary effects of mass treatment with azithromycin to eliminate blindness due to trachoma in Nepal. Clin Infect Dis 2002; 35:395-402.
32. Kiddugavu MG, Kiwanuka N, Wawer MJ, Serwadda D, Sewankambo NKWabwire-Mangen F. Effectiveness of syphilis treatment using azithromycin and/or benzathine penicillin in Rakai, Uganda. Sex Transm Dis 2005; 32:1-6.
33. Riedner G, Rusizoka M, Todd J, et al. Single-dose azithromycin versus penicillin G benzathine for the treatment of early syphilis. N Engl J Med 2005; 353:1236-44.
34. Van Damme K, Behets F, Ravelomanana N, et al. Evaluation of azithromycin resistance in Treponema pallidum specimens from Madagascar. Sex Transm Dis 2009; 36:775-6.
35. Mabey D. Oral azithromycin for treatment of yaws. Lancet 2012; 379:295-7.
36. Skalet AH, Cevallos V, Ayele B, et al. Antibiotic selection pressure and macrolide resistance in nasopharyngeal Streptococcus pneumoniae: a cluster-randomized clinical trial. PLoS Med 2010; 7:e1000377.
37. Leach AJ, Shelby-James TM, Mayo M, et al. A prospective study of the impact of community-based azithromycin treatment of trachoma on carriage and resistance of Streptococcus pneumoniae. Clin Infect Dis 1997; 24:356-62.
38. Haug S, Lakew T, Habtemariam G, et al. The decline of pneumococcal resistance after cessation of mass antibiotic distributions for trachoma. Clin Infect Dis 2010; 51:571-4.
39. Batt SL, Charalombous BM, Solomon AW, et al. Impact of azithromycin administration for trachoma control on the carriage of antibiotic resistant Streptococcus pneumoniae. Antimicrob Agents Chemother 2003; 47:2765-9.
40. Hotez PJ, Molyneux DH, Fenwick A, et al. Control of neglected tropical diseases. N Engl J Med 2007; 357:1018-27.
41. Amsden GW, Gregory T, Michalak C, Glue P, Knirsch C. Pharmacokinetics of azithromycin and the combination of ivermectin and albendazole when administered alone and concurrently in healthy volunteers. Am J Trop Med Hyg 2007; 76:1153-7.
42. El-Tahtawy A, Glue P, Andrews EN, Mardekian J, Amsden GW, Knirsch CA. The effect of azithromycin on ivermectin pharmacokinetics-a population pharmacokinetic model analysis. PLoS Negl Trop Dis 2008; 2:e236.
43. Edwards G, Awadzi K, Breckenridge AM, Adjepon-Yamoah K, Orme MLWard S. Diethylcarbamazine disposition in patients with onchocerciasis. Clin Pharmacol Ther 1981; 30:551-7.
44. Pfizer Labs. Zithromax (azithromycin) tablets (250 and 500 mg) and for oral suspension (100 or 200 mg/5 mL) prescribing information. New York: Pfizer, 2007.
45. World Health Organization. Elimination of yaws in India. Wkly Epidemiol Rec 2008; 83:125-32.